163 related articles for article (PubMed ID: 23514827)
1. Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants.
Akiyoshi T; Ito M; Murase S; Miyazaki M; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Pharmacokinet; 2013; 28(5):411-5. PubMed ID: 23514827
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent inhibition of CYP3A4-mediated midazolam metabolism by macrolide antibiotics in CYP3A4 genetic variants: Comparison with testosterone metabolism.
Akiyoshi T; Naitou R; Imaoka A; Miyazaki M; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Int J Clin Pharmacol Ther; 2021 Dec; 59(12):745-752. PubMed ID: 34542401
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
4. Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin.
Ishikawa Y; Akiyoshi T; Imaoka A; Ohtani H
Biopharm Drug Dispos; 2017 Oct; 38(7):420-425. PubMed ID: 28425104
[TBL] [Abstract][Full Text] [Related]
5. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis.
Wang RW; Newton DJ; Scheri TD; Lu AY
Drug Metab Dispos; 1997 Apr; 25(4):502-7. PubMed ID: 9107550
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
Akiyoshi T; Saito T; Murase S; Miyazaki M; Murayama N; Yamazaki H; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Dispos; 2011 Apr; 39(4):724-8. PubMed ID: 21212239
[TBL] [Abstract][Full Text] [Related]
7. Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4.
Burt HJ; Pertinez H; Säll C; Collins C; Hyland R; Houston JB; Galetin A
Drug Metab Dispos; 2012 Sep; 40(9):1658-67. PubMed ID: 22621802
[TBL] [Abstract][Full Text] [Related]
8. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based inhibition of CYP3A subfamilies by macrolide antibiotics and piperine.
Niwa T; Ishii R
Drug Metab Bioanal Lett; 2022 Aug; ():. PubMed ID: 36043771
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inhibition of recombinant human cytochrome P450 3A4 by tomato juice extract.
Sunaga K; Ohkawa K; Nakamura K; Ohkubo A; Harada S; Tsuda T
Biol Pharm Bull; 2012; 35(3):329-34. PubMed ID: 22382318
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants.
Yamaguchi Y; Akiyoshi T; Kawamura G; Imaoka A; Miyazaki M; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Pharmacokinet; 2021 Jun; 38():100384. PubMed ID: 33826998
[TBL] [Abstract][Full Text] [Related]
12. Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6
Kumondai M; Gutiérrez Rico EM; Hishinuma E; Ueda A; Saito S; Saigusa D; Tadaka S; Kinoshita K; Nakayoshi T; Oda A; Abe A; Maekawa M; Mano N; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2021 Mar; 49(3):212-220. PubMed ID: 33384383
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition.
Taesotikul T; Dumrongsakulchai W; Wattanachai N; Navinpipat V; Somanabandhu A; Tassaneeyakul W; Tassaneeyakul W
Drug Metab Pharmacokinet; 2011; 26(2):154-61. PubMed ID: 21178301
[TBL] [Abstract][Full Text] [Related]
16. Amino acid 305 determines catalytic center accessibility in CYP3A4.
Fowler SM; Riley RJ; Pritchard MP; Sutcliffe MJ; Friedberg T; Wolf CR
Biochemistry; 2000 Apr; 39(15):4406-14. PubMed ID: 10757990
[TBL] [Abstract][Full Text] [Related]
17. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis.
Dalbøge CS; Nielsen XC; Dalhoff K; Alffenaar JW; Duno M; Buchard A; Uges DR; Jensen AG; Jürgens G; Pressler T; Johansen HK; Høiby N
J Cyst Fibros; 2014 Mar; 13(2):179-85. PubMed ID: 24035278
[TBL] [Abstract][Full Text] [Related]
19. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
20. IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.
Burt HJ; Galetin A; Houston JB
Xenobiotica; 2010 May; 40(5):331-43. PubMed ID: 20230210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
